Literature DB >> 27924667

Contraceptive practices in women with sickle-cell disease.

Natália S Carvalho1, Josefina Pellegrini Braga2, Márcia Barbieri1, Maria R Torloni1, Maria S Figueiredo3, Cristina A F Guazzelli1.   

Abstract

This was a cross-sectional study of sexually active women with sickle-cell disease (SCD) managed at São Paulo Federal University during a one-year period. A total of 54 women were included. Mean age was 32.0 (11.2, standard deviation) years and almost 95% were black or of mixed racial ancestry. Almost 80% reported a history of multiple blood transfusions, 50% had kidney disease and 17% had a history of thrombosis. Over 80% of them had used some form of contraception, mostly combined hormonal contraceptive (52%) or progestin-only contraceptives (46%). Although most women had multiple comorbidities which would contraindicate the use of combined hormonal contraceptives, this was the most popular method used by them. We did not identify an association between the use of combined hormonal contraceptives and major complications. Larger, prospective studies are needed to evaluate the use and the effects of contraceptive methods in women with SCD.

Entities:  

Keywords:  Hormonal oral contraceptive; anaemia; combined oral contraceptives; sickle-cell anaemia

Mesh:

Substances:

Year:  2016        PMID: 27924667     DOI: 10.1080/01443615.2016.1225023

Source DB:  PubMed          Journal:  J Obstet Gynaecol        ISSN: 0144-3615            Impact factor:   1.246


  2 in total

Review 1.  Knowledge gaps in reproductive and sexual health in girls and women with sickle cell disease.

Authors:  Lydia H Pecker; Deva Sharma; Alecia Nero; Michael J Paidas; Russell E Ware; Andra H James; Kim Smith-Whitley
Journal:  Br J Haematol       Date:  2021-07-07       Impact factor: 8.615

2.  Megestrol Acetate Induced Paradoxical Embolism in a Sickle Cell Disease Patient.

Authors:  Lisette Dominguez; Furkan Tatar; Shahdi K Malakooti; Robert P Kulchinsky
Journal:  Cureus       Date:  2019-06-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.